We also examined the anti-epileptiform activity of the subtype selective 5-HT1D-, 5-HT2A- and 5-HT2C-antagonists without combinatorial FA treatment (i.e., single treatment) as other studies have shown that blocking these receptor subtypes can protect against seizures in other seizure/epilepsy models. This evidence concerns the gene HTR2A and epilepsy.